Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study
NCT ID: NCT02257450
Last Updated: 2016-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2500 participants
OBSERVATIONAL
2014-10-31
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimizing Diagnosis Of Primary Aldosteronism
NCT02755519
The Prevalence and Characteristics of Adrenal Incidentaloma
NCT04682938
Pathological Type,Gene Mutation and Clinical Characteristics of Unilateral Primary Aldosteronism
NCT06597630
Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism
NCT00173082
The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism
NCT00451672
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This will translate to a major impact to the Malaysian health-care budget. The costs spent on life-long BP medications and complications related to HPT can be reduced enormously. PA is a type of hormonal disorder that leads to high blood pressure (BP). In PA, the adrenal glands produce too much aldosterone causing sodium retention and potassium excretion. The excess sodium then increased the blood volume and BP.
Diagnosis and treatment of this condition are of paramount importance because people with this form of high BP have a higher risk of heart attack, stroke, kidney impairment, metabolic abnormality and reduce quality of life compared to patients with high BP not due to this condition. More importantly, the high BP associated with PA may be curable. This research will be conducted as a multicenter nation-wide study in Malaysia. The research aimed to study the prevalence of this disease in the investigators Malaysian population, determine the underlying mechanisms why this disease is associated with higher complication rate through cardiovascular and inflammatory markers, and identify the genes causing this disease, hence provide a more rapid diagnostic test and possibility of curing the disease with genetic therapy
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Malaysian citizen
* Consent given
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Malaysian Endocrine and Metabolic Society
OTHER
National University of Malaysia
OTHER
University of Malaya
OTHER
IMU University, Malaysia
OTHER
International Islamic University Malaysia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Mohamnmad Arif Shahar
Assist Prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nor Azmi Kamaruddin, FACE
Role: PRINCIPAL_INVESTIGATOR
Malaysian Endocrine and Metabolic Society
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MyEndo - PA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.